Walleye Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Walleye Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,882	Closed	-$276K	–	5108
2025 Q2	$276K	Buy	5,882 +1,642	+39%	+$73K	﹤0.01%	3114
2025 Q1	$187K	Sell	4,240 -153,789	-97%	-$7.08M	﹤0.01%	3309
2024 Q4	$5.71M	Sell	158,029 -128,064	-45%	-$4.47M	0.01%	986
2024 Q3	$9.17M	Buy	286,093 +286,027	+433,374%	+$10.7M	0.02%	743
2024 Q2	$2.49K	Sell	66 -1,881	-97%	-$79.2K	﹤0.01%	5403
2024 Q1	$95.8K	Buy	+1,947	New	+$90K	﹤0.01%	4412
2023 Q4	–	Sell	-144,307	Closed	-$3.34M	–	5492
2023 Q3	$3.34M	Buy	144,307 +95,694	+197%	+$2.62M	0.01%	1336
2023 Q2	$1.27M	Buy	+48,613	New	+$1.28M	﹤0.01%	1646
2022 Q3	–	Sell	-65,949	Closed	-$1.62M	–	3530
2022 Q2	$1.62M	Buy	+65,949	New	+$2.41M	0.04%	433

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Walleye Capital's SWTX Position: Q3 2025 in Review

Walleye Capital sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 5,882 shares — an estimated $276K sold.

Walleye Capital first reported a position in SWTX in Q2 2022 and held it in 9 quarters. The position peaked at $9.17M in Q3 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Walleye Capital reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 5,882 SpringWorks Therapeutics shares in Q3 2025, an estimated $276K.
Walleye Capital first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 9 quarters.
Walleye Capital's SpringWorks Therapeutics position peaked at $9.17M in Q3 2024.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.